

=> fil reg
FILE 'REGISTRY' ENTERED AT 15:09:22 ON 25 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 24 AUG 2004 HIGHEST RN 732209-96-0
DICTIONARY FILE UPDATES: 24 AUG 2004 HIGHEST RN 732209-96-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d sta que 15
L1 41 SEA FILE=REGISTRY ABB=ON PLU=ON (FGLM) / SQEP
L2 10 SEA FILE=REGISTRY ABB=ON PLU=ON L1 NOT METHIONINAMIDE
L3 3 SEA FILE=REGISTRY ABB=ON PLU=ON L2 AND (C27H43N5O7S OR
C22H35N5O5S)
L4 31 SEA FILE=REGISTRY ABB=ON PLU=ON L1 NOT L2
L5 34 SEA FILE=REGISTRY ABB=ON PLU=ON (L3 OR L4)


=> d sqide can tot 15

L5 ANSWER 1 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
RN 161167-60-8 REGISTRY
CN L-Methioninamide, N-(methoxycarbonyl)-L-phenylalanyl-(S)-2-methoxyglycyl-L-
leucyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 4
NTE modified (modifications unspecified)

SEQ 1 FGLM
=====
HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C25 H39 N5 O7 S
SR CA
LC STN Files: CA, CAPLUS, CASREACT
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 123:83977

REFERENCE 2: 122:161300

L5 ANSWER 2 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN

RN 157653-52-6 REGISTRY

CN L-Methioninamide, L-phenylalanyl-N-[3-[[[(1,1-dimethylethoxy) carbonyl] amino]propyl]glycyl-L-leucyl- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 4

NTE modified

type	-----	location	-----	description
terminal mod.	Met-4	-		C-terminal amide
modification	Gly-2	-		undetermined modification

SEQ 1 FGLM

====

HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C30 H50 N6 O6 S


SR CA

LC STN Files: CA, CAPLUS, USPATFULL

DT.CA CAplus document type: Patent

RLD.P Roles for non-specific derivatives from patents: PREP (Preparation)

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 121:206022

L5 ANSWER 3 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 157653-51-5 REGISTRY
 CN L-Methioninamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-phenylalanyl-N-[[[(1,1-dimethylethoxy)carbonyl]amino]propyl]glycyl-L-leucyl- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 4
 NTE modified


 type ----- location ----- description

 terminal mod. Met-4 - C-terminal amide
 modification Phe-1 - (9h-fluoren-9-ylmethoxy) carbonyl
 modification Gly-2 - undetermined modification

SEQ 1 FGLM
 =====
 HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK
 MF C45 H60 N6 O8 S
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL
 DT.CA CAplus document type: Patent
 RLD.P Roles for non-specific derivatives from patents: PREP (Preparation)

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


REFERENCE 1: 121:206022

L5 ANSWER 4 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 140171-05-7 REGISTRY
 CN L-Methioninamide, N-[2-[[2-[(1,1-dimethylethoxy)carbonyl]methylamino]-1-oxo-3-phenylpropyl]amino]ethyl]-L-leucyl-, (S)- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE
 SQL 4
 NTE modified

type	location	description
terminal mod.	Met-4	C-terminal amide
modification	Phe-1	methyl<Me>
modification	Phe-1	(1,1-dimethylethoxy) carbonyl<Boc>
modification	Gly-2	undetermined modification

SEQ 1 FGLM
 =====
 HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK
 MF C28 H47 N5 O5 S
 SR CA
 LC STN Files: BEILSTEIN*, CA, CAPLUS
 (*File contains numerically searchable property data)
 DT.CA CAplus document type: Journal
 RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 116:174745

L5 ANSWER 5 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 138200-19-8 REGISTRY
 CN L-Methioninamide, L-phenylalanylglycyl-L-leucyl-N-methyl- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 4
 NTE modified (modifications unspecified)


SEQ 1 FGLM
 =====

HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C23 H37 N5 O4 S
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER
 DT.CA CAplus document type: Journal
 RL.NP Roles from non-patents: PREP (Preparation)

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 116:34693

L5 ANSWER 6 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 117922-71-1 REGISTRY
 CN L-Methioninamide, N-[(1,1-dimethylethoxy)carbonyl]-D-phenylalanylglycyl-D-leucyl- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 4
 NTE modified

type	-----	location	-----	description
terminal mod.	Met-4	-		C-terminal amide
modification	Phe-1	-		(1,1-dimethylethoxy) carbonyl<Boc>

SEQ 1 FGLM
 =====

HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C27 H43 N5 O6 S


SR CA

LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
(*File contains numerically searchable property data)

DT.CA CAplus document type: Journal

RL.NP Roles from non-patents: PREP (Preparation)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 110:8651

L5 ANSWER 7 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN

RN 117904-53-7 REGISTRY

CN L-Methioninamide, D-phenylalanylglycyl-D-leucyl-, monohydrochloride (9CI)
(CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 4

NTE modified

type	-----	location	-----	description
terminal mod.	Met-4	-		C-terminal amide
modification	-	-		undetermined modification

SEQ 1 FGLM

=====

HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C22 H35 N5 O4 S . Cl H


SR CA

LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
(*File contains numerically searchable property data)

DT.CA CAplus document type: Journal

RL.NP Roles from non-patents: PREP (Preparation)

Absolute stereochemistry.



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 110:8651

L5 ANSWER 8 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 117904-48-0 REGISTRY
 CN L-Methioninamide, D-phenylalanylglycyl-L-leucyl-, monohydrochloride (9CI)
 (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 4
 NTE modified


 type ----- location ----- description

 terminal mod. Met-4 - C-terminal amide
 modification - - undetermined modification

SEQ 1 FGLM
 =====
 HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK
 MF C22 H35 N5 O4 S . Cl H
 SR CA
 LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
 (*File contains numerically searchable property data)
 DT.CA CAplus document type: Journal
 RL.NP Roles from non-patents: PREP (Preparation)

Absolute stereochemistry.



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 110:8651


L5 ANSWER 9 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 117904-47-9 REGISTRY
 CN L-Methioninamide, N-[(1,1-dimethylethoxy)carbonyl]-D-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 4
 NTE modified

type	----- location -----	description
terminal mod.	Met-4	- C-terminal amide
modification	Phe-1	- (1,1-dimethylethoxy) carbonyl<Boc>

SEQ 1 FGLM
 =====
 HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK
 MF C27 H43 N5 O6 S
 SR CA
 LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
 (*File contains numerically searchable property data)
 DT.CA CAplus document type: Journal
 RL.NP Roles from non-patents: PREP (Preparation)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 110:8651

L5 ANSWER 10 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 112259-85-5 REGISTRY
 CN Butanamide, L-phenylalanylglycyl-L-leucyl-4-(methylsulfinyl)-L-2-amino-,
 mono(trifluoroacetate) (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 4
 NTE modified

type	-----	location	-----	description
terminal mod.	Met-4	-		C-terminal amide
modification	-	-		undetermined modification
modification	Met-4	-		oxygen<O>


SEQ 1 FGLM
 =====
 HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK
 MF C22 H35 N5 O5 S . C2 H F3 O2
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA CAplus document type: Journal
 RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)


CM 1

CRN 77205-64-2
 CMF C22 H35 N5 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O21 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 108:56580

L5 ANSWER 11 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
RN 109003-54-5 REGISTRY
CN L-Methioninamide, L-phenylalanylglycyl-L-leucyl-, monoformate (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Formic acid, compd. with L-phenylalanylglycyl-L-leucyl-L-methioninamide (1:1) (9CI)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 4

NTE modified

type	-----	location	-----	description
terminal mod.	Met-4	-		C-terminal amide
modification	-	-		undetermined modification

SEQ 1 FGLM

=====

HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C22 H35 N5 O4 S . C H2 O2

SR CA

LC STN Files: CA, CAPLUS, CASREACT

DT.CA CAplus document type: Journal


RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

CM 1

CRN 51165-03-8

CMF C22 H35 N5 O4 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 107:40313


L5 ANSWER 12 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 109003-53-4 REGISTRY
 CN L-Methioninamide, N-[(phenylmethoxy)carbonyl]-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 4
 NTE modified

type	-----	location	-----	description
terminal mod.	Met-4	-		C-terminal amide
modification	Phe-1	-		(phenylmethoxy)carbonyl<Z>

SEQ 1 FGLM
 =====
 HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK
 MF C30 H41 N5 O6 S
 SR CA
 LC STN Files: CA, CAPLUS, CASREACT
 DT.CA CAplus document type: Journal
 RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 107:40313


L5 ANSWER 13 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 106847-80-7 REGISTRY
 CN L-Methioninamide, N-formyl-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX
 NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 4
 NTE modified

type	-----	location	-----	description
terminal mod.	Phe-1	-		N-formyl
terminal mod.	Met-4	-		C-terminal amide

SEQ 1 FGLM
 =====
 HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK
 MF C23 H35 N5 O5 S
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA CAplus document type: Journal
 RL.NP Roles from non-patents: PREP (Preparation)

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 106:82917


L5 ANSWER 14 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 105088-13-9 REGISTRY
 CN L-Methioninamide, 3-oxo-N-(5-oxo-2-pyrrolidinyl)-L-2-(phenylmethyl)- β -alanyl-L-phenylalanylglycyl-L-leucyl-, (R) - (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE
 SQL 4
 NTE modified

type	-----	location	-----	description
terminal mod.	Met-4	-		C-terminal amide
modification	Phe-1	-		undetermined modification

SEQ 1 FGLM
 =====
 HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK
 MF C36 H49 N7 O7 S
 SR CA
 LC STN Files: BEILSTEIN*, CA, CAPLUS
 (*File contains numerically searchable property data)
 DT.CA CAplus document type: Journal
 RL.NP Roles from non-patents: PROC (Process)

PAGE 1-A



PAGE 1-B

— CH₂ — SMe

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 105:203345

L5 ANSWER 15 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 97054-10-9 REGISTRY
 CN L-Methioninamide, L-phenylalanylglycyl-N-methyl-L-leucyl- (9CI) (CA INDEX


NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 4
NTE modified

type	-----	location	-----	description
terminal mod.	Met-4	-		C-terminal amide
modification	Leu-3	-		methyl<Me>

SEQ 1 FGLM
=====

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C23 H37 N5 O4 S
LC STN Files: CA, CAPLUS
DT CA CAPLUS document type: Conference
RL NP Roles from non-patents: BIOL (Biological study)

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 103:32413

L5 ANSWER 16 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
RN 88815-32-1 REGISTRY
CN L-Methioninamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanylglycyl-N-methyl-L-leucyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 4
NTE modified


type	----- location -----	description
terminal mod.	Met-4	- C-terminal amide
modification	Phe-1	(1,1-dimethylethoxy) carbonyl<Boc>
modification	Leu-3	methyl<Me>

SEQ 1 FGLM
=====

RELATED SEQUENCES AVAILABLE WITH SEQLINK
ME C28 H45 N5 O6 S

LC STN Files: CA, CAPLUS
 DT.CA CAplus document type: Journal
 RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study)

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 100:82211

L5 ANSWER 17 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 88319-69-1 REGISTRY
 CN L-Methioninamide, 4-chloro-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX
 NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 4
 NTE modified

type	----- location -----	description
terminal mod.	Met-4	- C-terminal amide
modification	Phe-1	- chloro<Cl>

SEQ 1 FGLM


=====

HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C22 H34 Cl N5 O4 S
 LC STN Files: CA, CAPLUS
 DT.CA CAplus document type: Conference
 RLD.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 100:34818


L5 ANSWER 18 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 88319-68-0 REGISTRY
 CN L-Methioninamide, 4-chloro-N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 4
 NTE modified

type	----- location -----	description
terminal mod.	Met-4	- C-terminal amide
modification	Phe-1	- (1,1-dimethylethoxy) carbonyl<Boc>
modification	Phe-1	- chloro<Cl>

SEQ 1 FGLM
 =====
 HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK
 MF C27 H42 Cl N5 O6 S
 LC STN Files: CA, CAPLUS
 DT.CA CAplus document type: Conference
 RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 100:34818

L5 ANSWER 19 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN


RN 82565-71-7 REGISTRY
 CN L-Methioninamide, 4-iodo-L-phenylalanylglycyl-L-leucyl-, monohydrochloride
 (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 4
 NTE modified

type	----- location -----	description
terminal mod.	Met-4	- C-terminal amide
modification	-	undetermined modification
modification	Phe-1	iodo<I>

SEQ 1 FGLM
 =====
 HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK
 MF C22 H34 I N5 O4 S . Cl H
 LC STN Files: CA, CAPLUS
 DT.CA CAplus document type: Journal
 RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 97:128063


L5 ANSWER 20 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 82565-70-6 REGISTRY
 CN L-Methioninamide, N-[(1,1-dimethylethoxy)carbonyl]-4-iodo-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 4
 NTE modified

type	----- location -----	description
terminal mod.	Met-4	- C-terminal amide
modification	Phe-1	(1,1-dimethylethoxy) carbonyl<Boc>
modification	Phe-1	iodo<I>

SEQ 1 FGLM
=====
HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C27 H42 I N5 O6 S
LC STN Files: CA, CAPLUS
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 97:128063


L5 ANSWER 21 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
RN 79794-15-3 REGISTRY
CN L-Methioninamide, N-(1-oxo-3-phenylpropyl)-L-phenylalanylglycyl-L-leucyl-
(9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 4
NTE modified

type	-----	location	-----	description
terminal mod.	Met-4	-		C-terminal amide
modification	Phe-1	-		1-oxo-3-phenylpropyl

SEQ 1 FGLM
=====
HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C31 H43 N5 O5 S
LC STN Files: CA, CAPLUS
DT.CA CAplus document type: Conference; Journal
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 97:208670

REFERENCE 2: 95:204417


L5 ANSWER 22 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
RN 79775-20-5 REGISTRY
CN L-Methioninamide, 3-oxo-N-(5-oxo-2-pyrrolidinyl)-2-(phenylmethyl)-β-alanyl-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 4
NTE modified

type	location		description
terminal mod.	Met-4	-	C-terminal amide
modification	Phe-1	-	undetermined modification

SEQ 1 FGLM
=====

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C36 H49 N7 O7 S
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)
DT.CA CAplus document type: Conference; Journal
RL.NP Roles from non-patents: PREP (Preparation); PRP (Properties)

PAGE 1-A



PAGE 1-B

— CH₂—SMe

4 REFERENCES IN FILE CA (1907 TO DATE)
 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 98:198713
 REFERENCE 2: 98:54466
 REFERENCE 3: 97:72750
 REFERENCE 4: 95:204417


L5 ANSWER 23 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 77750-24-4 REGISTRY
 CN L-Methioninamide, N-[1-(6-amino-9H-purin-9-yl)-1-deoxy- β -D-ribofuranuronoyl]-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE
 SQL 4
 NTE modified

type	----- location -----	description
terminal mod.	Met-4	- C-terminal amide
modification	Phe-1	- undetermined modification

SEQ 1 FGLM
 =====
 HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK
 MF C32 H44 N10 O8 S
 LC STN Files: CA, CAPLUS
 DT.CA CAplus document type: Journal
 RL.NP Roles from non-patents: BIOL (Biological study)

PAGE 1-A



PAGE 1-B

— CH₂ — SMe

2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 95:74138

REFERENCE 2: 95:74137

L5 ANSWER 24 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN

RN 77205-64-2 REGISTRY

CN Butanamide, L-phenylalanylglycyl-L-leucyl-2-amino-4-(methylsulfinyl)-, (2S)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Butanamide, L-phenylalanylglycyl-L-leucyl-4-(methylsulfinyl)-L-2-amino-

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 4

NTE modified

type	-----	location	-----	description
terminal mod.	Met-4	-		C-terminal amide
modification	Met-4	-		oxygen<O>

SEQ 1 FGLM

=====

HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C22 H35 N5 O5 S


CI COM

LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Conference; Journal

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:33136

REFERENCE 2: 94:175486

L5 ANSWER 25 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 73148-98-8 REGISTRY
 CN L-Methioninamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 4
 NTE modified


type	-----	location	-----	description
terminal mod.	Met-4	-		C-terminal amide
modification	Phe-1	-		(1,1-dimethylethoxy) carbonyl<Boc>

SEQ 1 FGLM
 =====
 HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C27 H43 N5 O6 S
 LC STN Files: BEILSTEIN*, CA, CAPLUS
 (*File contains numerically searchable property data)
 DT.CA CAplus document type: Conference; Journal; Patent
 RLD.P Roles for non-specific derivatives from patents: PREP (Preparation);
 RACT (Reactant or reagent)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation);
 RACT (Reactant or reagent)

Absolute stereochemistry.



14 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 14 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 122:106509

REFERENCE 2: 115:159806

REFERENCE 3: 115:9311

REFERENCE 4: 114:247769
 REFERENCE 5: 108:22254
 REFERENCE 6: 106:82917
 REFERENCE 7: 104:142385
 REFERENCE 8: 102:143288
 REFERENCE 9: 102:7076
 REFERENCE 10: 100:34818

L5 ANSWER 26 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 66013-29-4 REGISTRY
 CN Butanamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanylglycyl-L-leucyl-4-(methylsulfinyl)-L-2-amino- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:
 CN Butanamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanylglycyl-L-leucyl- γ -(methylsulfinyl)-L- α -amino-

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 4

NTE modified

type	----- location -----	description
terminal mod.	Met-4	- C-terminal amide
modification	Phe-1	(1,1-dimethylethoxy) carbonyl<Boc>
modification	Met-4	oxygen<O>

SEQ 1 FGLM
 =====

HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK


MF C27 H43 N5 O7 S

LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Conference; Journal

RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.



3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 108:56580

REFERENCE 2: 94:175486

REFERENCE 3: 88:152973

L5 ANSWER 27 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN

RN 61265-68-7 REGISTRY

CN L-Methioninamide, L-phenylalanylglycyl-L-leucyl-, monoacetate (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 4

NTE modified

type	-----	location	-----	description
terminal mod.	Met-4	-	-	C-terminal amide
modification	-	-	-	undetermined modification

SEQ 1 FGLM

=====

HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C22 H35 N5 O4 S . C2 H4 O2

LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Journal


RL.NP Roles from non-patents: PREP (Preparation)

CM 1

CRN 51165-03-8

CMF C22 H35 N5 O4 S


Absolute stereochemistry.



CM 2

CRN 64-19-7

CMF C2 H4 O2



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 86:16936

L5 ANSWER 28 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 61243-23-0 REGISTRY
 CN L-Methioninamide, N-[(2-hydroxy-5-methylphenyl)phenylmethylene]-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 4
 NTE modified


type	----- location -----	description
terminal mod.	Met-4	C-terminal amide
modification	Phe-1	undetermined modification

SEQ 1 FGLM
 =====

HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK
 MF C36 H45 N5 O5 S
 LC STN Files: BEILSTEIN*, CA, CAPLUS
 (*File contains numerically searchable property data)
 DT.CA CAplus document type: Journal
 RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.
 Double bond geometry unknown.



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 86:16936

L5 ANSWER 29 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 58290-61-2 REGISTRY
 CN L-Methioninamide, L-phenylalanylglycyl-L-leucyl-N-(diphenylmethyl)- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 4
 NTE modified (modifications unspecified)

SEQ 1 FGLM


=====

HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C35 H45 N5 O4 S

Absolute stereochemistry.



L5 ANSWER 30 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 58290-60-1 REGISTRY
 CN L-Methioninamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanylglycyl-L-leucyl-N-(diphenylmethyl)- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 4
 NTE modified (modifications unspecified)


type	----- location -----	description
modification	Phe-1	(1,1-dimethylethoxy) carbonyl<Boc>

SEQ 1 FGLM
 =====
 HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C40 H53 N5 O6 S

Absolute stereochemistry.




L5 ANSWER 31 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 58172-54-6 REGISTRY
 CN L-Methioninamide, L-phenylalanylglycyl-L-leucyl-, monohydrochloride (9CI)
 (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 4
 NTE modified

type	----- location -----	description
terminal mod.	Met-4	C-terminal amide
modification	-	undetermined modification

SEQ 1 FGLM
 =====
 HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK
 MF C22 H35 N5 O4 S . Cl H
 LC STN Files: BEILSTEIN*, CA, CAPLUS
 (*File contains numerically searchable property data)
 DT.CA CAplus document type: Conference; Journal; Patent
 RL.P Roles from patents: RACT (Reactant or reagent)
 RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)
 CRN (51165-03-8)

Absolute stereochemistry.



● HCl

12 REFERENCES IN FILE CA (1907 TO DATE)
 12 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 115:159745
 REFERENCE 2: 108:22254
 REFERENCE 3: 102:143288
 REFERENCE 4: 102:7076
 REFERENCE 5: 98:54466
 REFERENCE 6: 97:72750

REFERENCE 7: 94:150778

REFERENCE 8: 93:47158

REFERENCE 9: 92:129294

REFERENCE 10: 89:24823

L5 ANSWER 32 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN

RN 51165-04-9 REGISTRY

CN L-Methioninamide, L-phenylalanylglycyl-L-leucyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Acetic acid, trifluoro-, compd. with L-phenylalanylglycyl-L-leucyl-L-methioninamide (1:1)

OTHER NAMES:

CN H-Phe-Gly-Leu-Met-NH₂ trifluoroacetate

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 4

NTE modified

type	-----	location	-----	description
terminal mod.	Met-4	-		C-terminal amide
modification	-	-		undetermined modification

SEQ 1 FGLM

=====

HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C22 H35 N5 O4 S . C2 H F3 O2

LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Journal


RL.NP Roles from non-patents: BIOL (Biological study)

CM 1

CRN 51165-03-8

CMF C22 H35 N5 O4 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 80:78584

L5 ANSWER 33 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 51165-03-8 REGISTRY
 CN L-Methioninamide, L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 2: PN: WO03048192 SEQID: 2 claimed protein
 CN 8-11-Substance P
 CN H-Phe-Gly-Leu-Met-NH2
 CN Substance P (8-11)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 4
 NTE modified

type	location	description
terminal mod.	Met-4	C-terminal amide

PATENT ANNOTATIONS (PNTE):


Sequence	Patent
Source	Reference
Not Given	WO2003048192
	claimed
	SEQID 2

SEQ 1 FGLM
 =====
 HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C22 H35 N5 O4 S
 CI COM
 LC STN Files: CA, CAPLUS, CASREACT, CHEMCATS, DDFU, DRUGU, IFICDB, IFIPAT, IFIUDB, MSDS-OHS, TOXCENTER, USPATFULL
 DT.CA CAplus document type: Conference; Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 RLD.P Roles for non-specific derivatives from patents: PREP (Preparation); RACT (Reactant or reagent)
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
 RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); USES (Uses)

Absolute stereochemistry.



80 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 81 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:13355
 REFERENCE 2: 139:30851
 REFERENCE 3: 138:21218
 REFERENCE 4: 136:189375
 REFERENCE 5: 132:330223
 REFERENCE 6: 132:141952
 REFERENCE 7: 131:125600
 REFERENCE 8: 130:307061
 REFERENCE 9: 130:205446
 REFERENCE 10: 130:191898

L5 ANSWER 34 OF 34 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 42001-52-5 REGISTRY
 CN L-Methioninamide, N-[(4-methoxyphenyl)methoxy]carbonyl-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 4
 NTE modified


 type ----- location ----- description

 terminal mod. Met-4 - C-terminal amide
 modification Phe-1 - [(4-methoxyphenyl)methoxy]carbonyl<Moz>

SEQ 1 FGLM
 =====
 HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK
 DR 51165-23-2
 MF C31 H43 N5 O7 S
 LC STN Files: BEILSTEIN*, CA, CAPLUS
 (*File contains numerically searchable property data)
 DT.CA CAplus document type: Journal
 RL.NP Roles from non-patents: PREP (Preparation)

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 80:78584

REFERENCE 2: 79:19090

=> d his

(FILE 'HOME' ENTERED AT 14:56:39 ON 25 AUG 2004)
 SET COST OFF

FILE 'REGISTRY' ENTERED AT 14:56:49 ON 25 AUG 2004
 E FGML/SQEP

L1 41 S E3
 L2 10 S L1 NOT METHIONINAMIDE
 L3 3 S L2 AND (C27H43N5O7S OR C22H35N5O5S)
 L4 31 S L1 NOT L2
 L5 34 S L3,L4
 SAV L5 SZP053/A

FILE 'HCAPLUS' ENTERED AT 15:00:13 ON 25 AUG 2004

L6 119 S L5
 E WELLS I/AU
 L7 0 S E3,E4,E14,E15 AND L6
 E MAG /PA,CS
 E MAGN /PA,CS
 E MAGNES /PA,CS
 E MAGNESIUM/PA,CS
 L8 1 S E27-E30
 L9 0 S L6 AND L8
 L10 114 S L6 AND (PD<=19990310 OR PRD<=
 L11 104 S L10 NOT P/DT
 L12 10 S L10 NOT L11

114 references

in CAS!

 Limited to
 Patents only

FILE 'USPATFULL, USPAT2' ENTERED AT 15:04:51 ON 25 AUG 2004

L13 10 S L5

FILE 'REGISTRY' ENTERED AT 15:05:09 ON 25 AUG 2004

L14 3 S L5 AND USPAT?/LC

FILE 'USPATFULL' ENTERED AT 15:05:29 ON 25 AUG 2004
 SET SMARTSELECT ON
 L15 SEL L13 1- RN : 80 TERMS
 SET SMARTSELECT OFF

FILE 'REGISTRY' ENTERED AT 15:05:30 ON 25 AUG 2004
 L16 75 S L15
 L17 0 S L16 AND L5

FILE 'USPATFULL, USPAT2' ENTERED AT 15:05:54 ON 25 AUG 2004
 SEL RN L13

FILE 'REGISTRY' ENTERED AT 15:06:03 ON 25 AUG 2004
 L18 75 S E1-E80
 L19 0 S L18 AND L5

FILE 'USPATFULL, USPAT2' ENTERED AT 15:06:21 ON 25 AUG 2004

FILE 'USPATFULL' ENTERED AT 15:06:34 ON 25 AUG 2004
 L20 10 S L5

FILE 'REGISTRY' ENTERED AT 15:06:54 ON 25 AUG 2004

FILE 'USPATFULL' ENTERED AT 15:06:55 ON 25 AUG 2004
 SET SMARTSELECT ON
 L21 SEL L20 1- RN : 78 TERMS
 SET SMARTSELECT OFF

FILE 'REGISTRY' ENTERED AT 15:06:55 ON 25 AUG 2004
 L22 78 S L21
 L23 3 S L22 AND L5

FILE 'HCAPLUS' ENTERED AT 15:07:11 ON 25 AUG 2004
 SEL HIT RN L12

FILE 'REGISTRY' ENTERED AT 15:07:17 ON 25 AUG 2004
 L24 5 S E81-E85
 L25 5 S L23, L24
 L26 82 S MG/MF

FILE 'HCAPLUS' ENTERED AT 15:07:54 ON 25 AUG 2004
 L27 2 S L26 AND L10
 L28 1 S US20030077658/PN
 SEL RN

FILE 'REGISTRY' ENTERED AT 15:08:38 ON 25 AUG 2004
 L29 3 S E86-E88

FILE 'HCAPLUS' ENTERED AT 15:09:05 ON 25 AUG 2004
 L30 199262 S L29

FILE 'REGISTRY' ENTERED AT 15:09:22 ON 25 AUG 2004

=> d 129 sqide can tot

L29 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2004 ACS on S | From authors
 RN 89671-31-8 REGISTRY
 CN L-Methioninamide, L-phenylalanyl-L-valylglycyl-L | 200300 77658 x
 NAME)

OTHER NAMES:

CN 6-10-Neurokinin α
 CN Phe-Val-Gly-Leu-Met-NH2
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 5
 NTE modified

 type ----- location ----- description

terminal mod. Met-5 - C-terminal amide

SEQ 1 FVGLM

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C27 H44 N6 O5 S

CI COM

LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, USPAT2, USPATFULL
(*File contains numerically searchable property data)


DT.CA CAplus document type: Conference; Journal; Patent

RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

RLD.P Roles for non-specific derivatives from patents: BIOL (Biological
study); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation);
PRP (Properties); RACT (Reactant or reagent)

Absolute stereochemistry.



12 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
12 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:82815

REFERENCE 2: 133:190228

REFERENCE 3: 124:165481

REFERENCE 4: 122:151508

REFERENCE 5: 121:108267

REFERENCE 6: 116:121078

REFERENCE 7: 113:224635

REFERENCE 8: 104:168810

REFERENCE 9: 104:142380

REFERENCE 10: 103:196387

RN 51165-05-0 REGISTRY
 CN L-Methioninamide, L-phenylalanyl-L-phenylalanylglycyl-L-leucyl- (9CI) (CA
 INDEX NAME)
 OTHER NAMES:
 CN 7-11-Substance P
 CN Phe-Phe-Gly-Leu-Met-NH₂
 CN Substance P pentapeptide
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 5
 NTE modified

 type ----- location ----- description


 terminal mod. Met-5 - C-terminal amide

SEQ 1 FFGLM

RELATED SEQUENCES AVAILABLE WITH SEQLINK

DR 78081-73-9
 MF C31 H44 N6 O5 S
 CI COM
 LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, CHEMCATS, CSCHEM, DDFU,
 DRUGU, IFICDB, IFIPAT, IFIUDB, MEDLINE, MSDS-OHS, TOXCENTER, USPAT2,
 USPATFULL
 (*File contains numerically searchable property data)
 DT.CA CAplus document type: Conference; Journal; Patent
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
 PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 RLD.P Roles for non-specific derivatives from patents: BIOL (Biological
 study); PREP (Preparation); PRP (Properties); RACT (Reactant or
 reagent); USES (Uses)
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
 study); FORM (Formation, nonpreparative); PREP (Preparation); PROC
 (Process); PRP (Properties); RACT (Reactant or reagent)
 RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological
 study); PRP (Properties)

Absolute stereochemistry.



165 REFERENCES IN FILE CA (1907 TO DATE)
 5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 166 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:341728

REFERENCE 2: 139:144282

REFERENCE 3: 138:21218

REFERENCE 4: 137:195720

REFERENCE 5: 136:366698

REFERENCE 6: 136:260222

REFERENCE 7: 136:227036

REFERENCE 8: 135:283312

REFERENCE 9: 134:82815

REFERENCE 10: 133:190228

L29 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2004 ACS on STN

RN 7439-95-4 REGISTRY

CN Magnesium (8CI, 9CI) (CA INDEX NAME)

OTHER NAMES:

CN Magnesium element

CN PK 31

CN PK 31 (magnesium)

CN Rieke's active magnesium

DR 14147-08-1, 67208-78-0, 199281-20-4, 298688-48-9

MF Mg

CI COM

LC STN Files: ANABSTR, AQUIRE, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, RTECS*, TOXCENTER, ULIDAT, USPAT2, USPATFULL, VETU, VTB

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

DT.CA CAplus document type: Book; Conference; Dissertation; Journal; Patent; Preprint; Report

RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); CMBI (Combinatorial study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)

RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); CMBI (Combinatorial study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)

RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); CMBI (Combinatorial study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

Mg

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

198923 REFERENCES IN FILE CA (1907 TO DATE)
6787 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
199111 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:150220

REFERENCE 2: 141:150173

REFERENCE 3: 141:150148

REFERENCE 4: 141:149989

REFERENCE 5: 141:149562

REFERENCE 6: 141:149508

REFERENCE 7: 141:149250

REFERENCE 8: 141:149014

REFERENCE 9: 141:148985

REFERENCE 10: 141:148354

=> fil uspatfull

FILE 'USPATFULL' ENTERED AT 15:10:12 ON 25 AUG 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 24 Aug 2004 (20040824/PD)

FILE LAST UPDATED: 24 Aug 2004 (20040824/ED)

HIGHEST GRANTED PATENT NUMBER: US6782553

HIGHEST APPLICATION PUBLICATION NUMBER: US2004163153

CA INDEXING IS CURRENT THROUGH 24 Aug 2004 (20040824/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 24 Aug 2004 (20040824/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2004

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2004

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<

>>> the earliest to the latest publication.

<<<

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> => d 120 bib abs hitstr tot

L20 ANSWER 1 OF 10 USPATFULL on STN
 AN 2004:66003 USPATFULL
 TI Backbone-cyclized BPI peptidomimetics
 IN Hornik, Vered, Rehovot, ISRAEL
 PA Peptor Limited, Rehovot, ISRAEL (non-U.S. corporation)
 PI US 6706862 B1 20040316
 AI US 2000-553028 20000420 (9)
 RLI Division of Ser. No. US 1995-569042, filed on 7 Dec 1995, now patented,
 Pat. No. US 6117974
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Wang, Andrew; Assistant Examiner: Friend, Tomas
 LREP Winston & Strawn LLP
 CLMN Number of Claims: 14
 ECL Exemplary Claim: 1
 DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
 LN.CNT 1110
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Novel backbone-cyclized BPI peptide analogs and methods of making the same by the use of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units used in the synthesis of these backbone-cyclized peptide analogs are N.sup.α-functionalized amino acids constructed to include a spacer and a terminal functional group. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. A plurality of these Nω-functionalized amino acids are incorporated into a library of peptide sequences, preferably during solid phase peptide synthesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 157653-51-5DP, MBHA resin-bound 157653-52-6DP, MBHA
 resin-bound
 (preparation of, as intermediate for backbone cyclic peptides as drugs)
 RN 157653-51-5 USPATFULL
 CN L-Methioninamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-phenylalanyl-N-[3-
 [(1,1-dimethylethoxy)carbonyl]amino]propylglycyl-L-leucyl- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



RN 157653-52-6 USPATFULL
 CN L-Methioninamide, L-phenylalanyl-N-[3-[(1,1-dimethylethoxy) carbonyl]amino]propyl]glycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 2 OF 10 USPATFULL on STN

AN 2003:258333 USPATFULL

TI Skin wound healing promoters

IN Nishida, Teruo, Ube-shi, JAPAN

Nakata, Katsuhiko, Ikoma-shi, JAPAN

Nakamura, Masatsugu, Ikoma-shi, JAPAN

PI US 2003181386 A1 20030925

AI US 2003-344199 A1 20030207 (10)
 WO 2001-JP6933 20010810

PRAI JP 2000-24289 20000810

JP 2000-361388 20001128

DT Utility

FS APPLICATION

LREP Frishauf Holtz Goodman & Chick, 25th Floor, 767 Third Avenue, New York,
 NY, 10017-2023

CLMN Number of Claims: 12

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 335

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides healing promoters for skin wounds such as rupture, abrasion, surgical incision, skin ulcer and burn. Coexistence of Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH_{sub.2} or Phe-Gly-Leu-Met-NH_{sub.2} with insulin-like growth factor-I exhibits a remarkable promotive action on healing the skin wounds. Accordingly, combined administration of at least one of the substance P analogs and pharmaceutically acceptable salts thereof with the insulin-like growth factor exhibits a promotive effect on epidermal extension and a promotive effect on healing the skin wounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 51165-03-8

(skin wound healing promoters containing substance P analogs and insulin-like growth factor-I)

RN 51165-03-8 USPATFULL

CN L-Methioninamide, L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 3 OF 10 USPATFULL on STN

AN 2003:207825 USPATFULL

TI Conformationally constrained backbone cyclized peptide analogs

IN Gilon, Chaim, Jerusalem, ISRAEL

Eren, Doron, Rehovot, ISRAEL

Zeltser, Irina, Jerusalem, ISRAEL

Seri-Levy, Alon, Jerusalem, ISRAEL

Bitan, Gal, Jerusalem, ISRAEL

Muller, Dan, Jerusalem, ISRAEL

PI US 2003144186 A1 20030731

AI US 2002-167723 A1 20020912 (10)

RLI Continuation of Ser. No. US 2000-580905, filed on 31 May 2000, GRANTED, Pat. No. US 6407059 Division of Ser. No. US 1998-120237, filed on 22 Jul 1998, GRANTED, Pat. No. US 6265375 Continuation of Ser. No. US 1995-488159, filed on 7 Jun 1995, GRANTED, Pat. No. US 5811392

PRAI IL 1994-109943 19940608

DT Utility

FS APPLICATION

LREP WINSTON & STRAWN, PATENT DEPARTMENT, 1400 L STREET, N.W., WASHINGTON, DC, 20005-3502

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 3436

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N.^{sup.α}(ω -functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N.^{sup.α}(ω -functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is specifically exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 157653-51-5DP, MBHA resin-bound 157653-52-6DP, MBHA resin-bound

(preparation of, as intermediate for backbone cyclic peptides as drugs)

RN 157653-51-5 USPATFULL

CN L-Methioninamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-phenylalanyl-N-[[(1,1-dimethylethoxy)carbonyl]amino]propylglycyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 157653-52-6 USPATFULL

CN L-Methioninamide, L-phenylalanyl-N-[3-[[[(1,1-dimethylethoxy) carbonyl]amino]propyl]glycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 4 OF 10 USPATFULL on STN

AN 2002:144235 USPATFULL

TI Conformationally constrained backbone cyclized peptide analogs

IN Gilon, Chaim, Jerusalem, ISRAEL

Eren, Doron, Rehovot, ISRAEL

Zeltser, Irina, Jerusalem, ISRAEL

Seri-Levy, Alon, Jerusalem, ISRAEL

Bitan, Gal, Jerusalem, ISRAEL

Muller, Dan, Jerusalem, ISRAEL

PA Peptor Limited, Rehovot, ISRAEL (non-U.S. corporation)

PI US 6407059 B1 20020618

AI US 2000-580905 20000531 (9)

RLI Division of Ser. No. US 1998-120237, filed on 22 Jul 1998, now patented,
Pat. No. US 6265375 Continuation of Ser. No. US 1995-488159, filed on 7
Jun 1995, now patented, Pat. No. US 5811392

PRAI IL 1994-109943 19940608

DT Utility

FS GRANTED

EXNAM Primary Examiner: Low, Christopher S. F.; Assistant Examiner: Gupta,
Anish

LREP Winston & Strawn
 CLMN Number of Claims: 6
 ECL Exemplary Claim: 1
 DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
 LN.CNT 3156

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N.sup.α(ω-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N.sup.α(ω-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is specifically exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 157653-51-5DP, MBHA resin-bound 157653-52-6DP, MBHA resin-bound

(preparation of, as intermediate for backbone cyclic peptides as drugs)

RN 157653-51-5 USPATFULL

CN L-Methioninamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-phenylalanyl-N-[3-[(1,1-dimethylethoxy)carbonyl]amino]propylglycyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 157653-52-6 USPATFULL

CN L-Methioninamide, L-phenylalanyl-N-[3-[(1,1-dimethylethoxy)carbonyl]amino]propylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 5 OF 10 USPATTFULL on STN
 AN 2001:116981 USPATTFULL
 TI Conformationally constrained backbone cyclized peptide analogs
 IN Gilon, Chaim, Jerusalem, Israel
 Eren, Doron, Rehovot, Israel
 Zeltser, Irina, Jerusalem, Israel
 Seri-Levy, Alon, Jerusalem, Israel
 Gitan, Gal, Jerusalem, Israel
 Muller, Dan, Jerusalem, Israel
 PA Yissum Research Development Co. of the Hebrew University, Jerusalem,
 Israel (non-U.S. corporation)
 Peptor Limited, Rehovot, Israel (non-U.S. corporation)
 PI US 6265375 B1 20010724
 AI US 1998-120237 19980722 (9)
 RLI Continuation of Ser. No. US 1995-488159, filed on 7 Jun 1995, now
 patented, Pat. No. US 5811392
 PRAI IL 1994-109943 19940608
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Low, Christopher S. F.; Assistant Examiner: Gupta,
 Anish
 LREP Pennie & Edmonds LLP
 CLMN Number of Claims: 17
 ECL Exemplary Claim: 1
 DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
 LN.CNT 3375
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Novel backbone cyclized peptide analogs are formed by means of bridging
 groups attached via the alpha nitrogens of amino acid derivatives to
 provide novel non-peptidic linkages. Novel building units disclosed are
 N.sup.α (ω-functionalized) amino acids constructed to
 include a spacer and a terminal functional group. One or more of these
 N.sup.α (ω-functionalized) amino acids are incorporated into
 a peptide sequence, preferably during solid phase peptide synthesis. The
 reactive terminal functional groups are protected by specific protecting
 groups that can be selectively removed to effect either
 backbone-to-backbone or backbone-to-side chain cyclizations. The
 invention is specifically exemplified by backbone cyclized bradykinin
 antagonists having biological activity. Further embodiments of the
 invention are somatostatin analogs having one or two ring structures
 involving backbone cyclization.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 157653-51-5DP, MBHA resin-bound 157653-52-6DP, MBHA
resin-bound

(preparation of, as intermediate for backbone cyclic peptides as drugs)

RN 157653-51-5 USPATFULL

CN L-Methioninamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-phenylalanyl-N-[3-
[(1,1-dimethylethoxy)carbonyl]amino]propylglycyl-L-leucyl- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 157653-52-6 USPATFULL

CN L-Methioninamide, L-phenylalanyl-N-[3-[(1,1-dimethylethoxy)carbonyl]amino
]propylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 6 OF 10 USPATFULL on STN

AN 1999:34193 USPATFULL

TI Conformationally constrained backbone cyclized peptide analogs

IN Gilon, Chaim, Jerusalem, Israel

Eren, Doron, Rehovot, Israel

Zeltser, Irina, Jerusalem, Israel

Seri-Levy, Alon, Jerusalem, Israel

Bitan, Gal, Jerusalem, Israel

Muller, Dan, Jerusalem, Israel

PA Peptor Ltd., Rehovot, Israel (non-U.S. corporation)

Yissum Research Development Co. of the Hebrew University, Jerusalem,
Israel (non-U.S. corporation)

PI US 5883293 19990316

AI US 1996-750331 19961205 (8)
 WO 1995-IB453 19950607
 19961205 PCT 371 date
 19961205 PCT 102(e) date
 PRAI IL 1994-109943 19940608
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Hill, Jr., Robert J.; Assistant Examiner: Marshall, S. G.
 LREP Pennie & Edmonds LLP
 CLMN Number of Claims: 15
 ECL Exemplary Claim: 1
 DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
 LN.CNT 2830


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N.sup.a (ω-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N.sup.a (ω-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 157653-51-5DP, MBHA resin-bound 157653-52-6DP, MBHA
 resin-bound
 (preparation of, as intermediate for backbone cyclic peptides as drugs)
 RN 157653-51-5 USPATFULL
 CN L-Methioninamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-phenylalanyl-N-[3-[(1,1-dimethylethoxy)carbonyl]amino]propylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157653-52-6 USPATFULL
 CN L-Methioninamide, L-phenylalanyl-N-[3-[(1,1-dimethylethoxy)carbonyl]amino]propylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 7 OF 10 USPATFULL on STN

AN 1999:24746 USPATFULL

TI Conformationally constrained backbone cyclized peptide analogs

IN Gilon, Chaim, Jerusalem, Israel

Eren, Doron, Rehovot, Israel

Zeltser, Irina, Jerusalem, Israel

Seri-Levy, Alon, Jerusalem, Israel

Bitan, Gal, Jerusalem, Israel

Muller, Dan, Jerusalem, Israel

PA Peptor Ltd., Rehovot, Israel (non-U.S. corporation)

Yissum Research Development Company of the Hebrew University, Jerusalem, Israel (non-U.S. corporation)

PI US 5874529 19990223

WO 9533765 19951214

AI US 1996-750328 19961205 (8)

WO 1995-IB455 19950608

19961205 PCT 371 date

19961205 PCT 102(e) date

PRAI IL 1994-109943 19940608

DT Utility

FS Granted

EXNAM Primary Examiner: Walsh, Stephen; Assistant Examiner: Lazar-Wesley, Eliane

LREP Pennie & Edmonds

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 3388

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N.sup.α (ω-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N.sup.α (ω-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 157653-51-5DP, MBHA resin-bound 157653-52-6DP, MBHA
resin-bound

(preparation of, as intermediate for backbone cyclic peptides as drugs)

RN 157653-51-5 USPATFULL

CN L-Methioninamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-phenylalanyl-N-[3-[(1,1-dimethylethoxy)carbonyl]amino]propylglycyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 157653-52-6 USPATFULL

CN L-Methioninamide, L-phenylalanyl-N-[3-[(1,1-dimethylethoxy)carbonyl]amino]propylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 8 OF 10 USPATFULL on STN

AN 1998:115707 USPATFULL

TI Conformationally constrained backbone cyclized peptide analogs

IN Gilon, Chaim, Jerusalem, Israel

Eren, Doron, Rehovot, Israel

Zeltser, Irina, Jerusalem, Israel

Seri-Levy, Alon, Jerusalem, Israel

Bitan, Gal, Jerusalem, Israel

Muller, Dan, Jerusalem, Israel

PA Yissum research Development Co. of the Hebrew University, Jerusalem, Israel (non-U.S. corporation)

Peptor Limited, Rehovot, Israel (non-U.S. corporation)
 PI US 5811392 19980922
 AI US 1995-488159 19950607 (8)
 PRAI IL 1994-109943 19940608
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Gupta, Anism
 LREP Pennie & Edmonds LLP
 CLMN Number of Claims: 19
 ECL Exemplary Claim: 1
 DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
 LN.CNT 3444

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N.^{sup.a} (ω -functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N.^{sup.a} (ω -functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 157653-51-5DP, MBHA resin-bound 157653-52-6DP, MBHA
 resin-bound

(preparation of, as intermediate for backbone cyclic peptides as drugs)

RN 157653-51-5 USPATFULL

CN L-Methioninamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-phenylalanyl-N-[3-[(1,1-dimethylethoxy)carbonyl]amino]propylglycyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 157653-52-6 USPATFULL

CN L-Methioninamide, L-phenylalanyl-N-[3-[(1,1-dimethylethoxy)carbonyl]amino]propylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 9 OF 10 USPATFULL on STN

AN 1998:22334 USPATFULL

TI Process for the preparation of backbone cyclic peptides

IN Gilon, Chaim, Jerusalem, Israel

Zelinger, Zvi, Jerusalem, Israel

Byk, Gerardo, Jerusalem, Israel

PA Yissum Research Development Company of the Hebrew University of Jerusalem, Jerusalem, Israel (non-U.S. corporation)

PI US 5723575 19980303

AI US 1995-444135 19950518 (8)

RLI Continuation of Ser. No. US 1992-955380, filed on 1 Oct 1992, now abandoned

PRAI IL 1991-99628 19911002

DT Utility

FS Granted

EXNAM Primary Examiner: Robinson, Douglas W.; Assistant Examiner: Nelson, Amy T.

CLMN Number of Claims: 21

ECL Exemplary Claim: 1

DRWN 3 Drawing Figure(s); 3 Drawing Page(s)

LN.CNT 1367

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Biologically active, backbone-cyclized peptides of the formula: ##STR1## wherein [AA] or [A.sup.1 A.sup.1] is a naturally occurring or synthetic amino acid residue, n or e is an integer of 1-10, m or d is 0 or an integer of 1-10, R is a naturally occurring or synthetic amino acid side-chain, E is a hydroxyl moiety or a carboxyl protecting group of a blocking group, optionally covalently attached to an insoluble polymeric support, and the circled line designates a spacer group of ##STR2## for formula I wherein M is --S--S--, --CO--NH-- or --S-- and p and q each is an integer of 2-10, or

--(CH₂.sub.2).sub.p --(M).sub.x --Y (IV)

for formula II wherein M is an amino or carboxyl group or a sulfur atom, p is an integer of 2-10, x is 0 or 1 and Y is a side-chain of a backbone amino acid. Also, processes for the preparation of these peptides and pharmaceutical compositions containing them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 157653-51-5DP, MBHA resin-bound 157653-52-6DP, MBHA resin-bound

(preparation of, as intermediate for backbone cyclic peptides as drugs)

RN 157653-51-5 USPATFULL

CN L-Methioninamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-phenylalanyl-N-[3-[(1,1-dimethylethoxy)carbonyl]amino]propylglycyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 157653-52-6 USPATFULL

CN L-Methioninamide, L-phenylalanyl-N-[3-[(1,1-dimethylethoxy)carbonyl]amino]propylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 10 OF 10 USPATFULL on STN

AN 75:3866 USPATFULL

TI ANALOGS OF SUBSTANCE P

IN Scandrett, Mal Scott, Elwood, Victoria, Australia

PA ICI Australia Limited, Victoria, Australia (non-U.S. corporation)

PI US 3862114 19750121

AI US 1972-288337 19720912 (5)

PRAI AU 1971-7106 19711122

AU 1972-9835 19720725

DT Utility

FS Granted

EXNAM Primary Examiner: Gotts, Lewis; Assistant Examiner: Suyat, Reginald J.

LREP Cushman, Darby & Cushman

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 421

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A peptide having between 3 and 12 inclusive amino acid residues wherein the carboxy terminal end of the peptide comprises the amino acid sequence of general formula 1:

R -- R.sup.3 -- R.sup.2 -- R.sup.1 -- NH.sub.2

R.sup.3 is glycine, R.sup.2 is L-leucine, R.sup.1 -NH.sub.2 is L-methionine amide, L-methionine sulphoxide amide, L-methionine sulphone amide, or L-seleno methionine amide, R is a peptide fragment containing 0 to 9 amino acid residues, except that the peptide of general formula 1 cannot be 'Substance P' and that when present the 4th amino acid residue from the carboxy terminal end is L-phenylalanine, L-tyrosine or L-isoleucine, the 5th amino acid residue is L-phenylalanine, or L-tyrosine, the 6th amino acid residue is L-glutamine, L-tyrosine, L-lysine or L-alanine, the 7th amino acid residue is L-glutamine, L-tyrosine, L-asparagine or L-aspartic acid, the 8th amino acid residue is L-lysine, L-proline or L-tyrosine, the 9th amino acid residue from the carboxy terminal end is L-lysine, L-tyrosine, L-aspartic acid or L-serine, the 10th amino acid residue is L-proline, L-alanine or L-tyrosine, the 11th amino acid residue is L-pyroglutamic, L-glutamine L-tyrosine or L-arginine and that the 12th amino acid residue is L-tyrosine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 51165-03-8P

(preparation and antihypertensive activity of)

RN 51165-03-8 USPATFULL

CN L-Methioninamide, L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> fil hcplus

FILE 'HCAPLUS' ENTERED AT 15:10:44 ON 25 AUG 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Aug 2004 VOL 141 ISS 9
 FILE LAST UPDATED: 24 Aug 2004 (20040824/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all hitstr tot 112

L12 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:84613 HCAPLUS
 DN 132:141952
 ED Entered STN: 04 Feb 2000
 TI Bioimplant formulations containing stearin
 IN Trigg, Timothy Elliot; Walsh, John Desmond; Rathjen, Deborah Ann
 PA Peptech Limited, Australia
 SO PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-20
 ICS A61K047-44
 CC 63-6 (Pharmaceuticals)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000004897	A1	20000203	WO 1999-AU585	19990720 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2336879	AA	20000203	CA 1999-2336879	19990720 <--
	AU 9948890	A1	20000214	AU 1999-48890	19990720 <--
	AU 755443	B2	20021212		
	BR 9912275	A	20010417	BR 1999-12275	19990720 <--
	EP 1104296	A1	20010606	EP 1999-932545	19990720 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002521331	T2	20020716	JP 2000-560890	19990720 <--
	ZA 2001000567	A	20020121	ZA 2001-567	20010119 <--
PRAI	AU 1998-4730	A	19980720	<--	
	AU 1998-4731	A	19980720	<--	
	AU 1999-324	A	19990513		
	WO 1999-AU585	W	19990720		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000004897	ICM	A61K031-20
	ICS	A61K047-44

AB A pharmaceutical and/or veterinary formulation comprising about 2-30 % (weight/weight) of at least 1 active agent, about 0.5-20.0% of a pore-forming agent and the balance stearin. Such formulations provide sustained release of the at least one active agent in humans and other animals for periods of 7 days up to about 2 yr. Stearin and lecithin were mixed with freeze-dried deslorelin. The mixed material was extruded by using a ram extruder and was equilibrated at 55°. The product was then extruded at a rate of 3 g over a 30-s period and cooled and the the long

rods produced were sectioned into lengths of the required weight. In dissolution tests, after an initial rapid release of deslorelin, a sustained release extending over a prolonged period (110 days) was achieved. The average daily rate of deslorelin release during the sustained release period was within the range 50-2 µg/day.

ST bioimplant formulation stearin; veterinary pharmaceutical stearin; lecithin GnRH stearin bioimplant formulation

IT Carbohydrates, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino sugars; bioimplant formulations containing stearin)

IT Drug delivery systems
(beads; bioimplant formulations containing stearin)

IT Analgesics
Antidepressants
Dissolution rate
Opioid antagonists
Vaccines
(bioimplant formulations containing stearin)

IT Amino acids, biological studies
Antigens
Carbohydrates, biological studies
Lecithins
Nucleic acids
Peptides, biological studies
Proteins, general, biological studies
Salts, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bioimplant formulations containing stearin)

IT Peptides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclic, angiopeptin-containing; bioimplant formulations containing stearin)

IT Drug delivery systems
(implants; bioimplant formulations containing stearin)

IT Gonadotropins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; bioimplant formulations containing stearin)

IT Anti-inflammatory agents
(nonsteroidal; bioimplant formulations containing stearin)

IT Drugs
(veterinary; bioimplant formulations containing stearin)

IT Proteins, general, biological studies
Vitamins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(water-soluble; bioimplant formulations containing stearin)

IT 33507-63-0, Substance P 116243-73-3, Endothelin 119418-04-1, Galanin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antagonists; bioimplant formulations containing stearin)

IT 50-33-9, Phenylbutazone, biological studies 50-99-7, Glucose, biological studies 53-86-1, Indomethacin 56-87-1, Lysine, biological studies 57-27-2, Morphine, biological studies 57-42-1, Meperidine 58-55-9, Theophylline, biological studies 58-55-9D, Theophylline, analogs 60-87-7, Promethazine 60-99-1, Methotriprazaine 61-68-7, Mefenamic acid 76-99-3, Methadone 77-07-6, Levorphanol 96-88-8, Mepivacaine 127-09-3, Sodium acetate 137-58-6, Lidocaine 146-54-3, Triflupromazine 465-65-6, Naloxone 530-78-9, Flufenamic acid 646-06-0D, Dioxolane, derivs. 4652-64-6 5104-49-4, Flurbiprofen 7757-82-6, Sodium sulfate, biological studies 9002-60-2, ACTH, biological studies 9002-60-2D, ACTH, fragments 9002-72-6, Growth hormone 9002-72-6D, Growth hormone, analogs 9004-65-3, HPMC 9007-12-9, Calcitonin 9007-12-9D, Calcitonin, analogs 9034-40-6, GnRH 9034-40-6D, LHRH, analogs 11096-26-7, Erythropoietin 11096-26-7D, Erythropoietin, analogs 11099-07-3, Stearin 12321-44-7, Porcine Calcitonin 13311-84-7, Eulexin 15972-60-8, Alanex 16590-41-3, Naltrexone 21215-62-3, Human Calcitonin

22071-15-4, Ketoprofen 24305-27-9, TRH 24305-27-9D, TRH, analogs
 26159-34-2, Naproxen sodium 26171-23-3, Tolmetin 29679-58-1,
 Fenoprofen 33369-31-2, Zomepirac 36505-84-7, Buspirone 36637-18-0,
 Etidocaine 38194-50-2, Sulindac 38396-39-3, Bupivacaine 47931-85-1,
 Salmon Calcitonin 51110-01-1, Somatostatin-14 51110-01-1D,
 Somatostatin, analogs 51165-03-8 51165-05-0 51165-07-2,
 6-11-Substance P 51165-09-4, 5-11-Substance P 53164-05-9, Acemetacin
 53714-56-0, Leuprolide 53749-60-3, 4-11-Substance P 54910-89-3,
 Fluoxetine 57773-63-4, Triptorelin 57773-65-6, Deslorelin
 57982-77-1, Buserelin 59865-13-3, Cyclosporin A 59865-13-3D,
 Cyclosporin, analogs 61869-08-7, Paroxetine 62571-86-2, Captopril
 65807-02-5, Goserelin 66866-63-5, Lutrelin 73573-88-3, Mevastatin
 75330-75-5, Lovastatin 75847-73-3, Enalapril 76547-98-3, Lisinopril
 76712-82-8, Histrelin 76932-56-4, Nafarelin 79217-60-0, Cyclosporin
 79902-63-9, Simvastatin 81093-37-0, Pravastatin 82768-85-2,
 Quinaprilat 83150-76-9, Octreotide 83928-76-1, Gepirone 87679-71-8,
 Trandolaprilat 93413-69-5, Venlafaxine 95153-31-4 108736-35-2,
 Lanreotide 114949-22-3, Activin 120287-85-6, Cetrorelix 124904-93-4,
 Ganirelix 127932-90-5, Ramorelix 135038-57-2, Fasidotril
 140703-49-7, Meterelin 144743-92-0, Teverelix 145599-86-6,
 Cerivastatin 167305-00-2, Omapatrilat 169494-85-3, Leptin
 169494-85-3D, Leptin, analogs 183552-38-7, Abarelix
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (bioimplant formulations containing stearin)

IT 57285-09-3, Inhibin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (fragments; bioimplant formulations containing stearin)

IT 9015-82-1
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; bioimplant formulations containing stearin)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


- (1) Hoffman-La Roche, F; WO 9408623 1994 HCPLUS
- (2) Novo Nordisk AS; US 5179079 1993 HCPLUS
- (3) Peptide Technology Limited; WO 9700693 1997 HCPLUS
- (4) Yamanouchi Pharmaceutical Co; US 4578391 1986 HCPLUS

IT 51165-03-8
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (bioimplant formulations containing stearin)

RN 51165-03-8 HCPLUS

CN L-Methioninamide, L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 2 OF 10 HCPLUS COPYRIGHT 2004 ACS on STN

AN 1999:126827 HCPLUS

DN 130:191898

ED Entered STN: 26 Feb 1999

TI Substance P inhibitors in combination with NMDA blockers for treating pain
 IN Caruso, Frank S.

PA Algos Pharmaceutical Corporation, USA
 SO PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K045-06
 ICS A61K031-485; A61K038-04; A61K031-13; A61K038-04; A61K031-485
 CC 1-11 (Pharmacology)
 Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9907413	A1	19990218	WO 1998-US10707	19980526 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG	
	AU 9876960	A1	19990301	AU 1998-76960	19980526 <--
PRAI	US 1997-55233P	P	19970811	<--	
	WO 1998-US10707	W	19980526	<--	

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	WO 9907413	ICM	A61K045-06
		ICS	A61K031-485; A61K038-04; A61K031-13; A61K038-04; A61K031-485

AB The analgesic effectiveness of a substance P receptor antagonist is significantly potentiated by administering a substance P receptor antagonist with a nontoxic NMDA receptor antagonist and/or a nontoxic substance that blocks at least one major intracellular consequence of NMDA receptor activation.
 ST substance P inhibitor NMDA blocker analgesic
 IT Tachykinin receptors
 (NK1 antagonists; substance P inhibitor-NMDA blocker combination for treating pain)
 IT Glutamate antagonists
 (NMDA antagonists; substance P inhibitor-NMDA blocker combination for treating pain)
 IT Glutamate receptors
 (RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process))
 (NMDA-binding; substance P inhibitor-NMDA blocker combination for treating pain)
 IT Peptides, biological studies
 (RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses))
 (amides; substance P inhibitor-NMDA blocker combination for treating pain)
 IT Amines, biological studies
 (RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses))
 (aromatic; substance P inhibitor-NMDA blocker combination for treating pain)
 IT Pain
 (chronic; substance P inhibitor-NMDA blocker combination for treating pain)
 IT Spiro compounds

Spiro compounds
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lactams; substance P inhibitor-NMDA blocker combination for treating pain)

IT Pain
(musculoskeletal or neuropathic; substance P inhibitor-NMDA blocker combination for treating pain)

IT Heterocyclic compounds
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitrogen; substance P inhibitor-NMDA blocker combination for treating pain)

IT Muscle, disease
Muscle, disease
(pain; substance P inhibitor-NMDA blocker combination for treating pain)

IT Amines, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polycyclic; substance P inhibitor-NMDA blocker combination for treating pain)

IT Peptides, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pseudopeptides; substance P inhibitor-NMDA blocker combination for treating pain)

IT Lactams
Lactams
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(spiro; substance P inhibitor-NMDA blocker combination for treating pain)

IT Narcotics
(substance P inhibitor-NMDA blocker combination and (non)narcotic analgesics for treating pain)

IT Analgesics
Antimigraine agents
Drug delivery systems
(substance P inhibitor-NMDA blocker combination for treating pain)

IT Peptides, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substance P inhibitor-NMDA blocker combination for treating pain)

IT Drug delivery systems
(sustained-release; substance P inhibitor-NMDA blocker combination for treating pain)

IT Drug interactions
(synergistic; substance P inhibitor-NMDA blocker combination for treating pain)

IT Polycyclic compounds
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tricyclic, fused, aromatic; substance P inhibitor-NMDA blocker combination for treating pain)

IT 72162-84-6, Prolyl endopeptidase

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; substance P inhibitor-NMDA blocker combination for
treating pain)

IT 50-33-9, Phenylbutazone, biological studies 50-78-2, Aspirin 53-86-1,
Indometacin 57-27-2, Morphine, biological studies 61-68-7, Mefenamic
acid 76-42-6, Oxycodone 76-57-3, Codeine 77-07-6, Levorphanol
103-90-2, Acetaminophen 125-28-0, Dihydrocodeine 125-29-1, Hydrocodone
561-27-3, Heroin 644-62-2, Meclofenamic acid 5104-49-4, Flurbiprofen
15307-86-5, Diclofenac 15687-27-1, Ibuprofen 21256-18-8, Oxaprozin
22071-15-4, Ketoprofen 22204-53-1, Naproxen 22494-27-5, Flufenisal
22494-42-4, Diflunisal 26171-23-3, Tolmetin 27203-92-5, Tramadol
29679-58-1, Fenoprofen 33369-31-2, Zomepirac 36322-90-4 36330-85-5,
Fenbufen 38194-50-2, Sulindac 41340-25-4, Etodolac 42924-53-8,
Nabumetone 74103-06-3, Ketorolac

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(substance P inhibitor-NMDA blocker combination and (non)narcotic
analgesics for treating pain)

IT 100-76-5D, Quinuclidine, derivs. 107-15-3D, Ethylenediamine, derivs.
110-85-0D, Piperazine, N,N-diacyl derivs., biological studies 110-89-4D,
Piperidine, derivs., biological studies 125-71-3, Dextromethorphan
125-73-5, Dextrorphan 491-38-3D, Chromone, derivs. 768-94-5,
Amantadine 4652-64-6 6238-14-8D, 3-Aminoquinuclidine, derivs.
19982-08-2, Memantine 21850-12-4D, Perhydroisoindole, derivs.
33507-63-0D, Substance P, analogs 49623-78-1D, Quinuclidinium, derivs.,
salts 51165-03-8 54012-73-6D, 3-Aminopiperidine, derivs.
80102-26-7 91224-37-2 94778-06-0 94778-07-1 94841-43-7
95384-45-5 95384-47-7 99590-92-8 100807-53-2 118121-64-5
124003-00-5 124003-06-1 124003-08-3 125989-12-0 129605-49-8
129605-51-2 129912-33-0 134731-58-1 135007-72-6 135807-32-8
135807-34-0 135911-02-3 135911-03-4 135911-04-5 135934-74-6
136870-97-8 136870-98-9 136870-99-0 136871-24-4 136871-25-5
136871-26-6 137380-73-5 141379-85-3 141379-86-4 141379-87-5
142849-14-7 142849-15-8 142849-27-2 144480-86-4 144480-87-5
144480-88-6 144600-86-2 144600-88-4 144600-90-8 145741-89-5
145741-98-6 145742-21-8 145742-23-0 145840-39-7 146031-37-0
146031-38-1 146031-54-1 146366-33-8 146366-34-9 146366-51-0
146366-53-2 146682-87-3 146725-78-2 147116-64-1 147116-65-2
147145-44-6 147145-46-8 147145-77-5 147148-27-4 147148-64-9
147249-22-7 147249-24-9 147353-93-3 147353-94-4 147354-05-0
147373-67-9 147373-68-0 147373-69-1 147611-45-8 147632-38-0
148033-89-0 148033-91-4 148102-55-0 148102-61-8 148102-67-4
148451-85-8 148451-86-9 148451-87-0 148451-88-1 148700-81-6
148700-82-7 148700-83-8 150705-54-7 150705-55-8 150705-56-9
150708-32-0 150708-33-1 150917-27-4 150917-28-5 151191-81-0
151191-85-4 151191-86-5 152298-79-8 152695-08-4 152695-09-5
156749-85-8 156749-86-9 156854-51-2 157811-47-7 160502-70-5
160502-76-1 160502-80-7 161253-50-5 161344-31-6 162203-64-7
162203-65-8 162203-66-9 167261-59-8 167261-61-2 167262-07-9
167262-08-0 167262-09-1 167262-10-4 167756-06-1 167756-07-2
167756-08-3 168271-17-8 168271-18-9 168271-19-0 172943-42-9
187799-06-0 187799-08-2 187799-12-8 189558-48-3 220766-23-4D,
1-Azabicyclo[3.2.2]nonan-3-amine, derivs. 220766-24-5 220766-25-6
220766-26-7 220766-27-8 220766-28-9 220766-29-0 220766-30-3
220766-31-4 220766-32-5 220766-33-6 220766-34-7 220766-35-8
220766-36-9 220766-37-0 220766-38-1 220766-39-2 220766-40-5
220766-41-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(substance P inhibitor-NMDA blocker combination for treating pain)

RE

- (1) Ashton, W; US 5292726 A 1994 HCPLUS
- (2) Murray; Pain 1991, V44(2), P179 HCPLUS
- (3) Okano; Biol Pharmaceut Bull 1995, V18(1), P42 HCPLUS
- (4) Price, D; Pain 1996, V68(1), P119 HCPLUS
- (5) Ren; Brit J Pharmacol 1996, V117(1), P196 HCPLUS

IT 51165-03-8


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(substance P inhibitor-NMDA blocker combination for treating pain)

RN 51165-03-8 HCPLUS

CN L-Methioninamide, L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 3 OF 10 HCPLUS COPYRIGHT 2004 ACS on STN

AN 1998:42295 HCPLUS

DN 128:80004

ED Entered STN: 24 Jan 1998

TI Ophthalmic drug compositions

IN Nishida, Teruo; Nakamura, Masatsugu; Nakata, Katsuhiko

PA Santen Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 19 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

IC ICM A61K038-07

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9749419	A1	19971231	WO 1997-JP2015	19970611 <--
	W: CA, CN, KR, NO, US			RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE	
	JP 10017489	A2	19980120	JP 1996-165612	19960626 <--
	JP 3191038	B2	20010723		
	EP 914827	A1	19990512	EP 1997-926223	19970611 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	JP 1996-165612	A	19960626		<--
	WO 1997-JP2015	W	19970611		<--

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	WO 9749419	ICM	A61K038-07
AB	The min. activity-exhibiting site of substance P has now been found and the action of a compound consisting of the units constituting the min. site on the ophthalmic region has been elucidated, on the basis of which the		

following ophthalmic drug compns. containing the above compound as the active ingredient are provided: an ophthalmic drug composition (particularly corneal disease remedy) containing as the active ingredient Phe-Gly-Leu-Met-NH₂ or a pharmaceutically acceptable salt thereof; and a corneal disease remedy (particularly elongation accelerator for corneal epithelium) containing as the active ingredients Phe-Gly-Leu-Met-NH₂ or a pharmaceutically acceptable salt thereof and insulin-like growth factor I. These preps. preferably take the dosage form of eye drops.

ST eye lotion peptide growth factor; insulin like growth factor eye lotion; cornea disease eye lotion

IT Eye, disease
(keratopathy; ophthalmic drug compns.)

IT Drug delivery systems
(solns., ophthalmic; ophthalmic drug compns.)


IT 51165-03-8 67763-96-6, Insulin-like growth factor I
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ophthalmic drug compns.)

IT 51165-03-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ophthalmic drug compns.)

RN 51165-03-8 HCPLUS

CN L-Methioninamide, L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 4 OF 10 HCPLUS COPYRIGHT 2004 ACS on STN
AN 1994:606022 HCPLUS
DN 121:206022
ED Entered STN: 29 Oct 1994
TI Preparation of backbone cyclic peptides as drugs and pharmaceutical compositions containing them.
IN Gilon, Chaim; Zelinger, Zvi; Byk, Gerardo
PA Hebrew University of Jerusalem, Israel
SO Eur. Pat. Appl., 48 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM C07K007-22
ICS C07K007-56; A61K037-24
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1

FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 564739	A2	19931013	EP 1992-309016	19921002 <--
	EP 564739	A3	19950426		

EP 564739	B1	20000126		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 06263797	A2	19940920	JP 1992-304347	19921002 <--
JP 3509029	B2	20040322		
AU 754476	B2	20021114	AU 2000-27711	20000412 <--
PRAI IL 1991-99628	A	19911002	<--	



CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

EP 564739	ICM	C07K007-22
	ICS	C07K007-56; A61K037-24

OS MARPAT 121:206022

GI



AB Title compds. I [n = 1-10 integer; m = 0, 1-10 integer; AA, A1A1 = amino acid residue; R = amino acid side-chain; E = protecting group], NK-1 receptors selective tachykinin agonists, useful for treatment of pain, inflammation, Alzheimer's disease, familial dysautonomia, Parkinson's disease, and tardive dyskinesia (no data), are prepared via removing the protecting group L from G-NH-(CH2)_q-NL-CHR-CO₂H or G-NH-(CH2)_q-NL-CHR-CONH[A1A1]_m-CO-E [G, L = protecting group] and reacting the product with J-NH-[AA]_n-CO₂H [J = protecting group], selectively removing the protecting group J from J-NH-[AA]_n-CO-N[(CH2)_q-NH-G]-CHR-CO-NH-[A1A1]_m-CO-E, reacting the resulting NH₂-[AA]_n-CO-N[(CH2)_q-NH-G]-CHR-CO-NH-[A1A1]_m-CO-E with HO-CO-(CH2)_p-CO₂H [p = 2-10 integer], selectively removing the protecting group G from the resulting HO-CO-(CH2)_p-CONH-[AA]_n-CO-N[(CH2)_q-NH-G]-CHR-CO-NH-[A1A1]_m-CO-E, and cyclizing the resulting HO-CO-(CH2)_p-CONH-[AA]_n-CO-N[(CH2)_q-NH₂]-CHR-CO-NH-[A1A1]_m-CO-E in the presence of a coupling agent, e.g., DCC. E.g., the title compound II was prepared by the solid-phase method on a preferred benzhydrylamine polystyrene 1% divinylbenzene polymer (MBHA). II had an EC₅₀ of 5 μM for the NK-1 subreceptor but >50,000 μM for the NI-2 subreceptor. General procedures are provided for the synthesis of many important intermediates.

ST backbone cyclic peptide prep drug; familial dysautonomia treatment cyclic peptide; Parkinson disease treatment cyclic peptide; Alzheimer disease treatment cyclic peptide; antiinflammatory backbone cyclic peptide; analgesic backbone cyclic peptide; tardive dyskinesia treatment cyclic peptide

IT Analgesics

Inflammation inhibitors
(backbone cyclic peptides)IT Parkinsonism
(treatment of, backbone cyclic peptides for)IT Mental disorder
(Alzheimer's disease, treatment of, backbone cyclic peptides for)

IT Peptides, preparation
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (cyclo-, preparation of, as drugs)

IT Nervous system
 (disease, familial dysautonomia, treatment of, backbone cyclic peptides
 for)

IT Nervous system
 (disease, tardive dyskinesia, treatment of, backbone cyclic peptides
 for)

IT Kinin receptors
 Receptors
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (tachykinin NK1, -selective, tachykinin agonists, backbone cyclic
 peptides as)

IT 136710-21-9P 141510-03-4P 157622-07-6P 157622-08-7P 157653-49-1P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
 study); PREP (Preparation); USES (Uses)
 (preparation of, as drug)

IT 2280-68-4DP, MBHA resin-bound 2488-15-5P, tert-Butyloxycarbonyl-L-
 methionine 4510-08-1DP, MBHA resin-bound 16217-56-4DP, MBHA
 resin-bound 24123-14-6P 34805-23-7DP, MBHA resin-bound 70889-93-9P
 90495-95-7P 128421-93-2P 128421-96-5P 143192-21-6P 143192-22-7P
 143192-23-8P 143192-24-9P 143192-25-0P 143192-26-1P 143192-27-2P
 143192-28-3P 143192-29-4P 143192-30-7P 143192-31-8P 143192-32-9P
 143192-33-0P 143192-34-1P 143192-36-3P 143192-37-4P 143192-38-5P
 143192-39-6P 143192-41-0P 143192-42-1P 143192-43-2P 144088-08-4P
 157622-06-5P 157622-09-8DP, MBHA resin-bound 157622-10-1DP, MBHA
 resin-bound 157622-11-2DP, MBHA resin-bound 157622-12-3DP, MBHA
 resin-bound 157622-13-4DP, MBHA resin-bound 157622-14-5DP, MBHA
 resin-bound 157622-15-6DP, MBHA resin-bound 157622-16-7DP, MBHA
 resin-bound 157622-17-8DP, MBHA resin-bound 157622-18-9DP, MBHA
 resin-bound 157622-19-0DP, MBHA resin-bound 157653-50-4DP, MBHA
 resin-bound 157653-51-5DP, MBHA resin-bound
 157653-52-6DP, MBHA resin-bound 157653-53-7DP, MBHA resin-bound
 157653-54-8DP, MBHA resin-bound 157653-55-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as intermediate for backbone cyclic peptides as drugs)


IT 56-84-8, Aspartic acid, reactions 61-90-5, Leucine, reactions 63-68-3,
 Methionine, reactions 63-91-2, Phenylalanine, reactions 74-79-3,
 Arginine, reactions 2875-41-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, in preparation of backbone cyclic peptides as drugs)

IT 157653-51-5DP, MBHA resin-bound 157653-52-6DP, MBHA
 resin-bound
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as intermediate for backbone cyclic peptides as drugs)

RN 157653-51-5 HCPLUS

CN L-Methioninamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-phenylalanyl-N-[3-
 [(1,1-dimethylethoxy)carbonyl]amino]propylglycyl-L-leucyl- (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.



RN 157653-52-6 HCPLUS

CN L-Methioninamide, L-phenylalanyl-N-[3-[[[(1,1-dimethylethoxy) carbonyl] amino]propyl]glycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 5 OF 10 HCPLUS COPYRIGHT 2004 ACS on STN

AN 1991:559806 HCPLUS

DN 115:159806

ED Entered STN: 18 Oct 1991

TI Preparation of an undecapeptide amide (substance P)

IN Beyermann, Michael; Bienert, Michael; Egler, Heinz; Haeupke, Klaus; Krause, Eberhard; Schwarz, Justus; Walz, Harry

PA Institut fuer Wirkstoffforschung, Ger. Dem. Rep.

SO Ger. (East), 8 pp.

CODEN: GEXXA8

DT Patent

LA German

IC ICM C07K007-06

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 2

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DD 285097	A5	19901205	DD 1989-329831	19890621 <--
PRAI DD 1989-329831		19890621	<--	
CLASS				
PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES		

DD 285097 ICM C07K007-06

OS MARPAT 115:159806

AB The title compound, H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂ (I), was prepared by coupling Z-Arg(NO₂)-OH (via the mixed anhydride) with proline, condensing the resulting Z-Arg(NO₂)-Pro-OH with the nonapeptide H-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-X-NH₂ [X = Met, Met(O)] supported on a benzhydrylamine resin, deblocking with HF and cleaving off the resin with dilute HOAc in the case where X = Met, or with CF₃CO₂H-DMF-HCl in the case where X = Met(O) or a mixture of Met and Met(O). Z-Arg(NO₂)-OH in DMF containing Et₃N was treated with ClCO₂CHMe₂, the resulting mixed anhydride condensed with proline in DMF containing HOBT, and the resulting dipeptide condensed with benzhydrylamine resin-bound H-Lys(Z)-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂. The resulting resin-bound undecapeptide was deblocked with HF and the crude undecapeptide extracted from the resin with dilute HCl. The preparation of I via sequential coupling of benzhydrylamine resin-bound H-Met-NH₂ with the corresponding BOC-protected amino acids is also detailed.

ST substance P; oxide substance P

IT 34805-23-7D, benzhydrylamine resin-bound

RL: RCT (Reactant); RACT (Reactant or reagent)
(deprotection of)

IT 34805-21-5

RL: RCT (Reactant); RACT (Reactant or reagent)
(peptide coupling of, in preparation of substance P oxide)

IT 147-85-3, Proline, reactions

RL: RCT (Reactant); RACT (Reactant or reagent)
(peptide coupling of, with arginine derivative)

IT 2304-98-5

RL: RCT (Reactant); RACT (Reactant or reagent)
(peptide coupling of, with proline)

IT 2280-68-4DP, benzhydrylamine resin-bound 3235-59-4DP, benzhydrylamine resin-bound 58172-64-8DP, benzhydrylamine resin-bound 64699-01-0DP, benzhydrylamine resin-bound 73148-98-8DP, benzhydrylamine resin-bound 73148-99-9DP, benzhydrylamine resin-bound 73149-00-5DP, benzhydrylamine resin-bound 78626-87-6DP, benzhydrylamine resin-bound
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and deprotection of, in preparation of substance P)

IT 67412-90-2DP, benzhydrylamine resin-bound

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and peptide coupling of, with arginylproline derivative)

IT 51165-05-0DP, benzhydrylamine resin-bound 51165-07-2DP, benzhydrylamine resin-bound
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and peptide coupling of, with glutamine derivative)

IT 16217-56-4DP, benzhydrylamine resin-bound

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and peptide coupling of, with glycine derivative)

IT 4510-08-1DP, benzhydrylamine resin-bound

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and peptide coupling of, with leucine derivative)

IT 53749-60-3DP, benzhydrylamine resin-bound

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and peptide coupling of, with lysine derivative)


IT 4652-64-6DP, benzhydrylamine resin-bound 51165-03-8DP,

benzhydrylamine resin-bound

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)
 (preparation and peptide coupling of, with phenylalanine derivative)
 IT 51165-09-4DP, benzhydrylamine resin-bound
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and peptide coupling of, with proline derivative)
 IT 33507-63-0P, Substance P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, via solid phase coupling of arginylproline derivative with nonapeptide amide)
 IT 42001-61-6DP, benzhydrylamine resin-bound
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation, deprotection, and resin cleavage of)
 IT 2389-45-9 4530-20-5 13139-15-6 13726-85-7 13734-34-4 15761-39-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (solid-phase peptide coupling of, in preparation of substance P)
 IT 73148-98-8DP, benzhydrylamine resin-bound
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and deprotection of, in preparation of substance P)
 RN 73148-98-8 HCAPLUS
 CN L-Methioninamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 51165-03-8DP, benzhydrylamine resin-bound
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and peptide coupling of, with phenylalanine derivative)
 RN 51165-03-8 HCAPLUS
 CN L-Methioninamide, L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 6 OF 10 HCPLUS COPYRIGHT 2004 ACS on STN
 AN 1978:424823 HCPLUS
 DN 89:24823
 ED Entered STN: 12 May 1984
 TI Peptides
 IN Isowa, Yoshikazu; Nagasawa, Takeshi; Kuroiwa, Katsumasa; Narita, Koichi
 PA Sagami Chemical Research Center, Japan; Nitto Boseki Co., Ltd.
 SO Patentschrift (Switz.), 9 pp.
 CODEN: SWXXAS

DT Patent
 LA German
 IC C07C103-52
 CC 34-3 (Synthesis of Amino Acids, Peptides, and Proteins)
 Section cross-reference(s): 7

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CH 597158	A	19780331	CH 1975-5383	19750425 <--
PRAI	CH 1975-5383			19750425	<--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
CH 597158	IC	C07C103-52

AB Peptides R-X-X1-X2-R1 [X = Ala, Gln, Asn, Leu, Gly, Glu, Glu(OMe), Pro, Lys(BOC) (BOC = Me₃CO₂C), X₃-X₄ (X₃ = hydrophilic amino acid residue; X₄ = Val, Met, Leu, Gln); X₁ = Phe, Tyr, Leu, Met, Glu, Asp, Gln, Asn, Trp; X₂ = Phe, Leu, Ile, Tyr, Cys(CH₂Ph), Ser(CH₂Ph), Trp, Met; R = α -amino acid protective group, N-terminal protected amino acid or peptide residue; R₁ = CO₂H-protective group, C-terminal protected amino acid or peptide residue] were prepared by coupling R-X-X1-OH to H-X₂-R1 by pepsin. Thus, BOC-Lys(BOC)-Phe-OH was coupled to H-Phe-Gly-Leu-Met-NH₂ by pepsin at 40° for 24 h to give 88.2% BOC-Lys(BOC)-Lys-Phe-Phe-Gly-Leu-Met-NH₂.

ST peptide coupling pepsin catalyst

IT Peptides, preparation

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, by pepsin-catalyzed peptide coupling reaction)

IT 9001-75-6

RL: CAT (Catalyst use); USES (Uses)
 (catalyst, for peptide coupling reaction)

IT	987-84-8	1738-78-9	2131-00-2	2280-71-9	2448-58-0	3417-91-2
	6458-56-6	7524-50-7	7524-52-9	16257-10-6	16741-80-3	18598-74-8
	19525-87-2	21285-27-8	24730-33-4	41041-68-3	50912-71-5	
	51165-03-8	58172-54-6	58172-55-7	58172-58-0		
	58172-59-1	58172-60-4	58172-62-6	58172-66-0	58172-67-1	
	58172-68-2	58172-70-6	58172-81-9	58172-83-1	58172-85-3	
	58172-87-5	58172-91-1	58172-92-2	58172-94-4	58172-95-5	
	58172-97-7	58172-99-9	58173-01-6	58173-03-8	58173-04-9	
	58173-05-0	58173-06-1	58173-07-2	58173-08-3	58173-09-4	
	58173-10-7	58173-11-8	58173-12-9	58173-13-0	58173-35-6	
	58173-36-7	58173-37-8	58173-38-9	58173-39-0	58173-40-3	
	58173-41-4	58173-43-6	58173-44-7	58173-45-8	58173-46-9	
	58173-47-0	58207-46-8	66884-02-4			

RL: RCT (Reactant); RACT (Reactant or reagent)
 (peptide coupling of, pepsin catalysis of)

IT 2753-99-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

IT	2575-69-1P	2937-03-3P	3708-54-1P	5899-56-9P	21853-73-6P
	36261-64-0P	42001-57-0P	58172-57-9P	58172-61-5P	58172-63-7P
	58172-64-8P	58172-65-9P	58172-69-3P	58172-71-7P	58172-72-8P
	58172-73-9P	58172-74-0P	58172-75-1P	58172-76-2P	58172-77-3P
	58172-78-4P	58172-79-5P	58172-80-8P	58172-82-0P	58172-84-2P

58172-86-4P 58172-88-6P 58172-89-7P 58172-90-0P 58172-93-3P
 58172-96-6P 58172-98-8P 58173-00-5P 58173-02-7P 58173-14-1P
 58173-15-2P 58173-16-3P 58173-17-4P 58173-18-5P 58173-19-6P
 58173-20-9P 58173-21-0P 58173-22-1P 58173-23-2P 58173-24-3P
 58173-25-4P 58173-26-5P 58173-27-6P 58173-28-7P 58173-29-8P
 58173-30-1P 58173-31-2P 58173-32-3P 58173-33-4P 58173-34-5P
 58173-42-5P 58173-48-1P 58173-49-2P 58173-50-5P 58173-51-6P
 58173-52-7P 58173-53-8P 58173-54-9P 66884-01-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, by pepsin-catalyzed peptide coupling reaction)


IT 51165-03-8 58172-54-6

RL: RCT (Reactant); RACT (Reactant or reagent)
 (peptide coupling of, pepsin catalysis of)

RN 51165-03-8 HCPLUS

CN L-Methioninamide, L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 58172-54-6 HCPLUS

CN L-Methioninamide, L-phenylalanylglycyl-L-leucyl-, monohydrochloride (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L12 ANSWER 7 OF 10 HCPLUS COPYRIGHT 2004 ACS on STN

AN 1977:502658 HCPLUS

DN 87:102658

ED Entered STN: 12 May 1984

TI Process for preparing peptides

PA Sagami Chemical Research Center, Japan

SO Brit., 18 pp.

CODEN: BRXXAA

DT Patent

LA English
 IC C07C103-52
 CC 34-3 (Synthesis of Amino Acids, Peptides, and Proteins)
 Section cross-reference(s): 16

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 1465235	A	19770223	GB 1975-17807	19750429 <--
PRAI	GB 1975-17807		19750429	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

GB 1465235	IC	C07C103-52
------------	----	------------

AB Sixty-four hepta-, hexa-, and lower peptides were prepared by coupling a terminal C-protected or free peptide with a terminal N-protected peptide in the presence of pepsin in a buffer solution of pH 2-6 at <50°. Thus, 1.5 mmol HCl.Phe-Gly-Leu-Met in citric acid buffer solution (pH 4.0) was added to 2.5 mmol α,ω -di-Boc-Lys-Phe (Boc = Me₃CO₂C) in 1N NaOH; subsequently H₂O and 0.2 g pepsin (1:5000) were added and the mixture stirred 24 h at 40° to give 88.2% α,ω -di-Boc-Lys-Phe-Gly-Leu-Met.

ST polypeptide coupling pepsin catalyst

IT Coupling reaction catalysts
 (pepsin, for peptides)

IT Peptides, preparation

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, by pepsin-catalyzed couplings)

IT 9001-75-6

RL: CAT (Catalyst use); USES (Uses)
 (catalyst, for coupling of peptides)

IT 1738-78-9 2131-00-2 2280-71-9 3417-91-2 6458-56-6 7524-50-7
 7524-52-9 16257-10-6 16741-80-3 18598-74-8 19525-87-2 24730-33-4
 41041-68-3 50912-71-5 58172-54-6 58172-60-4 58172-70-6
 58172-81-9 58172-85-3 58172-95-5 58173-35-6 58173-36-7
 58173-37-8 58173-38-9 58173-46-9 58173-47-0 58207-46-8
 58296-65-4 64019-66-5

RL: RCT (Reactant); RACT (Reactant or reagent)
 (coupling of, with terminal carbon-protected peptide, in presence of pepsin)

IT 987-84-8 2448-58-0 58172-55-7 58172-58-0 58172-59-1 58172-62-6
 58172-66-0 58172-67-1 58172-68-2 58172-83-1 58172-87-5
 58172-91-1 58172-92-2 58172-94-4 58172-97-7 58172-99-9
 58173-01-6 58173-03-8 58173-04-9 58173-05-0 58173-06-1
 58173-07-2 58173-08-3 58173-09-4 58173-10-7 58173-11-8
 58173-12-9 58173-13-0 58173-39-0 58173-40-3 58173-43-6
 58173-44-7 58173-45-8


RL: RCT (Reactant); RACT (Reactant or reagent)
 (coupling of, with terminal nitrogen-protected peptide, in presence of pepsin)

IT 2575-69-1P 2753-99-3P 2937-03-3P 3708-54-1P 5899-56-9P
 21853-73-6P 36261-64-0P 42001-57-0P 58172-56-8P 58172-57-9P
 58172-61-5P 58172-63-7P 58172-64-8P 58172-65-9P 58172-69-3P
 58172-71-7P 58172-72-8P 58172-73-9P 58172-74-0P 58172-75-1P
 58172-76-2P 58172-77-3P 58172-78-4P 58172-79-5P 58172-80-8P
 58172-82-0P 58172-84-2P 58172-86-4P 58172-88-6P 58172-89-7P
 58172-90-0P 58172-93-3P 58172-96-6P 58172-98-8P 58173-00-5P
 58173-02-7P 58173-14-1P 58173-15-2P 58173-16-3P 58173-17-4P
 58173-18-5P 58173-19-6P 58173-20-9P 58173-21-0P 58173-22-1P
 58173-23-2P 58173-24-3P 58173-25-4P 58173-26-5P 58173-27-6P
 58173-28-7P 58173-29-8P 58173-30-1P 58173-31-2P 58173-32-3P
 58173-33-4P 58173-34-5P 58173-42-5P 58173-48-1P 58173-49-2P
 58173-50-5P 58173-51-6P 58173-52-7P 58173-53-8P 58173-54-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)
 IT 58172-54-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (coupling of, with terminal carbon-protected peptide, in presence of
 pepsin)
 RN 58172-54-6 HCPLUS
 CN L-Methioninamide, L-phenylalanylglycyl-L-leucyl-, monohydrochloride (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L12 ANSWER 8 OF 10 HCPLUS COPYRIGHT 2004 ACS on STN

AN 1976:74618 HCPLUS

DN 84:74618

ED Entered STN: 12 May 1984

TI Peptides

IN Scandrett, Mal S.

PA ICI Australia Ltd., Australia

SO Pat. Specif. (Aust.), 20 pp.

CODEN: ALXXAP

DT Patent

LA English

IC A61K

CC 34-3 (Synthesis of Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
PI AU 466276	-----	19751023	AU 1972-46583	19711122 <--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
-----	-----	-----

AU 466276 IC A61K

AB R-Gly-Leu-Met-NH2 (I, R = H, H-Tyr, H-Phe, H-Gly-Phe, H-Tyr-Phe, H-Phe-Phe, H-Ala-Phe-Tyr, H-Gln-Phe-Phe, H-Asp-Ala-Phe-Tyr, R1-Gln-Gln-Phe-Phe, R1 = H, H-Pro, H-Tyr-Pro, H-Tyr-Arg-Pro-Lys-Pro, R2-Gln-Gln-Phe-Tyr, R2 = H, H-Pro, H-Arg-Pro-Lys-Pro with the N-terminal residue having the D-configuration and all others having the L-configuration), were prepared by the solid phase method and all I, except I (R = H), showed a 5-10 mm Hg decrease in the arterial pressure of the femoral artery in dogs after injection with 75 mg/min.

ST antihypertensive substance P analog; peptide substance P analog

IT Antihypertensives

(substance P analogs as)

IT L-Methioninamide, N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl-N-

(diphenylmethyl)-, resin bound derivative
 L-Methioninamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-L-phenylalanylglycyl-L-leucyl-N-(diphenylmethyl)-, resin bound derivative
 L-Methioninamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanylglycyl-L-leucyl-N-(diphenylmethyl)-, resin bound derivative
 L-Methioninamide, N-[(1,1-dimethylethoxy)carbonyl]glycyl-L-leucyl-N-(diphenylmethyl)-, resin bound derivative
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (deblocking of)

IT Butanamide, 2-amino-N-(diphenylmethyl)-4-(methylthio)-, resin bound derivative, (S)-
 L-Methioninamide, L-leucyl-N-(diphenylmethyl)-, resin bound derivative
 L-Methioninamide, L-phenylalanylglycyl-L-leucyl-N-(diphenylmethyl)-, resin bound derivative
 L-Methioninamide, glycyl-L-leucyl-N-(diphenylmethyl)-, resin bound derivative
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (peptide coupling reactions of)

IT Substance P (peptide), analogs
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and biol. activity of)


IT 4530-20-5 13139-15-6 13734-34-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (peptide coupling reactions of)

IT 4652-64-6P 6026-80-8P **51165-03-8P** 51165-05-0P 51165-07-2P
 51165-09-4P 53749-60-3P 55288-05-6P 55614-09-0P 55614-10-3P
 55614-11-4P 55614-12-5P 55614-13-6P 55614-15-8P 55614-16-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and biol. activity of)

IT **51165-03-8P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and biol. activity of)

RN 51165-03-8 HCAPLUS
 CN L-Methioninamide, L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1976:60004 HCAPLUS
 DN 84:60004
 ED Entered STN: 12 May 1984
 TI Peptide
 IN Isowa, Yoshikazu; Nagasawa, Takeshi; Kuroiwa, Katsumasa; Narita, Koichi
 PA Sagami Chemical Research Center, Japan; Nitto Boseki Co., Ltd.
 SO Ger. Offen., 34 pp.

CODEN: GWXXBX

DT Patent

LA German

IC C07C

CC 34-3 (Synthesis of Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 16

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2518256	A1	19751106	DE 1975-2518256	19750424 <--
	DE 2518256	B2	19800313		
	DE 2518256	C3	19801106		
	JP 50140686	A2	19751111	JP 1974-46261	19740424 <--
	JP 54043076	B4	19791218		
PRAI	JP 1974-46261		19740429	<--	

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	DE 2518256	IC C07C	

AB Oligopeptides (.apprx. 75 compds.) were prepared by standard coupling methods. Thus, Phe-Gly-NHNH₂.2HBr in citric acid buffer at pH 4 reacted with p-MeOC₆H₄CH₂O₂C-Ala-Phe-OH in 1N NaOH containing pepsin to give 61.2% p-MeOC₆H₄CH₂O₂C-Ala-Phe-Phe-Gly-NHNH₂.

ST peptide oligo pepsin coupling; oligopeptide pepsin coupling

IT Peptides, preparation

RL: PREP (Preparation)
(oligo, by pepsin)

IT 58172-68-2

RL: RCT (Reactant); RACT (Reactant or reagent)
(peptide coupling reaction of)

IT	987-84-8	1738-78-9	2131-00-2	2448-58-0	3417-91-2	6458-56-6
	7524-50-7	7524-52-9	16257-10-6	16741-80-3	18598-74-8	19525-87-2
	24730-33-4	41041-68-3	58172-54-6	58172-55-7	58172-58-0	
	58172-59-1	58172-60-4	58172-62-6	58172-66-0	58172-67-1	
	58172-70-6	58172-81-9	58172-83-1	58172-85-3	58172-87-5	
	58172-91-1	58172-92-2	58172-94-4	58172-95-5	58172-97-7	
	58172-99-9	58173-01-6	58173-03-8	58173-04-9	58173-05-0	
	58173-06-1	58173-07-2	58173-08-3	58173-09-4	58173-10-7	
	58173-11-8	58173-12-9	58173-13-0	58173-35-6	58173-36-7	
	58173-37-8	58173-38-9	58173-39-0	58173-40-3	58173-41-4	
	58173-43-6	58173-44-7	58173-45-8	58173-46-9	58173-47-0	
	58207-46-8	58296-65-4				

RL: RCT (Reactant); RACT (Reactant or reagent)
(peptide coupling reactions of)

IT 2937-03-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deblocking of)

IT	2575-69-1P	2753-99-3P	3708-54-1P	5899-56-9P	21853-73-6P
	36261-64-0P	42001-57-0P	58172-56-8P	58172-57-9P	58172-61-5P
	58172-63-7P	58172-64-8P	58172-65-9P	58172-69-3P	58172-71-7P
	58172-72-8P	58172-73-9P	58172-74-0P	58172-75-1P	58172-76-2P
	58172-77-3P	58172-78-4P	58172-79-5P	58172-80-8P	58172-82-0P
	58172-84-2P	58172-86-4P	58172-88-6P	58172-89-7P	58172-90-0P
	58172-93-3P	58172-96-6P	58172-98-8P	58173-00-5P	58173-02-7P
	58173-14-1P	58173-15-2P	58173-16-3P	58173-17-4P	58173-18-5P
	58173-19-6P	58173-20-9P	58173-21-0P	58173-22-1P	58173-23-2P
	58173-24-3P	58173-25-4P	58173-26-5P	58173-27-6P	58173-28-7P
	58173-29-8P	58173-30-1P	58173-31-2P	58173-32-3P	58173-33-4P
	58173-34-5P	58173-42-5P	58173-48-1P	58173-49-2P	58173-50-5P
	58173-51-6P	58173-52-7P	58173-53-8P	58173-54-9P	

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


IT 58172-54-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(peptide coupling reactions of)

RN 58172-54-6 HCPLUS

CN L-Methioninamide, L-phenylalanylglycyl-L-leucyl-, monohydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



● HCl

L12 ANSWER 10 OF 10 HCPLUS COPYRIGHT 2004 ACS on STN

AN 1975:410884 HCPLUS

DN 83:10884

ED Entered STN: 12 May 1984

TI Anlogs of substance P

IN Scandrett, Mal S.

PA ICI Australia Ltd., Australia

SO U.S., 6 pp.

CODEN: USXXAM

DT Patent

LA English

IC C07C; C07G; A61K

NCL 260112500

CC 34-3 (Synthesis of Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3862114	A	19750121	US 1972-288337	19720912 <--
PRAI	AU 1971-7106		19711122	<--	
	AU 1972-9835		19720725	<--	

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES		
	US 3862114	IC	C07CIC	C07GIC	A61K
		NCL	260112500		

AB Antihypertensive peptides, X1-Gly-Leu-X2-NH₂ (X1 = H or 1-9 amino acid residues; X2 = methionine residue or its sulfoxide, sulfone, or seleno analog) were prepared via solid-phase synthesis. Thus, Tyr-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂ (I) was prepared from the corresponding tert-butoxycarbonyl blocked amino acids on benzhydrylamine resin. I caused a mean fall arterial pressure decrease of 10 ± 2 mm Hg in dogs with an infusion of 75 ng/min.

ST selenomethionine peptide antihypertensive; antihypertensive peptide; substance P analog antihypertensive

IT Antihypertensives

(substance P analogs as)

IT Peptides, preparation
RL: PREP (Preparation)
(substance P analogs, antihypertensive activity of)

IT Substance P (peptide), analogs
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


IT 4652-64-6P 51165-03-8P 51165-05-0P 51165-07-2P 51165-09-4P
53749-60-3P 55288-05-6P 55614-09-0P 55614-10-3P 55614-11-4P
55614-12-5P 55614-13-6P 55614-14-7P 55614-15-8P 55614-16-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antihypertensive activity of)

IT 51165-03-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antihypertensive activity of)

RN 51165-03-8 HCPLUS

CN L-Methioninamide, L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> => s 128 and 130
L31 1 L28 AND L30

=> d all hitstr

L31 ANSWER 1 OF 1 HCPLUS COPYRIGHT 2004 ACS on STN
AN 2000:646243 HCPLUS
DN 133:190228
ED Entered STN: 15 Sep 2000
TI Method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses
IN Wells, Ibert C.
PA USA
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM G01N033-53
ICS G01N033-535
CC 9-16 (Biochemical Methods)
Section cross-reference(s): 14
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
PI WO 2000054053	A1	20000914	WO 2000-US3707	20000309

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
 CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
 IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
 MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 2001051345 A1 20011213 US 1999-265690 19990310
 US 6372440 B2 20000416
 EP 1181554 A1 20020227 EP 2000-919293 20000309
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 US 2003077658 A1 20030424 US 2002-53669 20020124 <--
 PRAI US 1999-265690 A 19990310
 WO 2000-US3707 W 20000309

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
-----	-----	-----
WO 2000054053	ICM	G01N033-53
	ICS	G01N033-535

AB This invention relates to methods for detecting the deficiency of magnesium tightly bound to cellular membranes, i.e. magnesium binding defect, which deficiency is associated with certain abnormal physiol. states, e.g., salt-sensitive essential hypertension or Type 2 diabetes mellitus.

ST detecting plasma membrane magnesium disease diagnose

IT Immunoassay
(Immunoenzyme assay; method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses)

IT Hypertension
(Salt-sensitive essential; method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses)

IT Immunoassay
(enzyme-linked immunosorbent assay; method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses)

IT Affinity
Blood analysis
Cell membrane
Diagnosis
Disease, animal
Fluorescent substances
Isotope indicators
(method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses)

IT Antibodies
Enzymes, uses
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses)

IT Antibodies
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(monoclonal; method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses)

IT Diabetes mellitus
(non-insulin-dependent; method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses)

IT 7439-95-4, Magnesium, analysis
RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses)

IT 51165-05-0 89671-31-8

RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Frickey; Preparation and Characterization of Monoclonal Antibodies to Substance Hybridoma 1991, V10(6), P685 HCPLUS
- (2) Theodorsson-Norheim; Biochemical and Biophysical Research Communications 1985, V131(1), P77 HCPLUS

IT 7439-95-4, Magnesium, analysis

RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
 (method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses)

RN 7439-95-4 HCPLUS

CN Magnesium (8CI, 9CI) (CA INDEX NAME)

Mg


IT 51165-05-0 89671-31-8

RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses)

RN 51165-05-0 HCPLUS

CN L-Methioninamide, L-phenylalanyl-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 89671-31-8 HCPLUS

CN L-Methioninamide, L-phenylalanyl-L-valylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>